Prompt pre-symptomatic identification of patients with class II BRAF mutations (i.e., higher risk of developing epilepsy or expressing a severe epileptic phenotype) is expected to help clinicians to a more effective disease management in terms of diagnosis, treatment and care, reducing the risks of associated complications and improving health outcomes. Here, BRAF is linked to epilepsy.